Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)

This study has been completed.
Sponsor:
Collaborator:
AGO Study Group
Information provided by (Responsible Party):
German Breast Group
ClinicalTrials.gov Identifier:
NCT00567554
First received: December 4, 2007
Last updated: February 9, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2015
  Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):